Aktienanalyse zu Park Ha Biological Technology Co Ltd (BYAH)BYAHPark Ha Biological Technology Co Ltd

Park Ha Biological Technology Co Ltd is an investment holding company primarily engaged in developing private skincare label, direct skincare products sales and franchise alliances promotions. The Company mainly operates its business through two segments. The Products Sales segment is engaged in providing skincare and cosmetic products under the brand name Park Ha as well as offering complimentary after-sales beauty services in physical stores. The Franchise Service segment is engaged in entering franchise agreements with its franchisees, pursuant to which the franchisees are granted permission to open and operate a store under the brand name Park Ha or Geni. The Company's products include Little Blue Injection Serum, Parkha Amino Acid Cleansing Foam and other products. The Company mainly conducts its business in domestic market. It operates in the Consumer Non-Cyclicals sector.

Given the current price of $2.75 and a staggering year-to-date change of -95.96%, this asset is not a good buy right now. The RSI is at 38.648, indicating it is nearing oversold territory, but the ongoing class action lawsuit poses a significant risk. The forward P/E ratio is at 0, suggesting uncertainty about future earnings, which further complicates the investment case.